Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.
about
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsAssessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.Dealing with the complex drug-drug interactions: towards mechanistic models.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways.Mechanisms and Consequences of Drug-Drug Interactions.Mechanism-Based Inhibition of CYP3A4 by Podophyllotoxin: Aging of an Intermediate Is Important for in Vitro/in Vivo Correlations.Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies.Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
P2860
Q26764739-EB537A3A-E87E-4DEB-A90F-E74491A86B0DQ34573885-2361DF4F-EA61-411F-A72E-06454C5CA73EQ38302225-6C961971-6319-430A-B0C7-F86FC1165BB2Q38346846-59E09EC2-8316-485F-9738-7AB3E1891DA9Q38800092-66E96ECF-5899-4F73-9BCC-B9B811A4570AQ39194285-5E79E805-FA47-4FC1-AC86-1F00BA76ECCFQ39247285-799E98BC-366A-4101-AB5D-A16D49A77B66Q40306549-8F6917A8-638F-4361-91CE-4625A445509FQ41432197-194D7BEF-F4E6-41FC-9A77-201E1F190F7DQ41451834-3A82A506-E8E2-469F-A1C0-CC15F1F244E1Q41962845-662A6094-E848-4B16-B21B-70E50294B5CAQ47420860-EA74E95F-FC38-47E7-9E66-BF52E00E410CQ47787457-F73569BA-E4A0-43F7-9641-71E83A4157DFQ50122460-FC6EDEEF-1145-4DBF-8D4D-1CE3A5EA6E33Q52334679-8344BE90-4FD4-486F-B22E-B93E0C420653
P2860
Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Evaluation of various static i ...... al of an investigational drug.
@en
Evaluation of various static i ...... al of an investigational drug.
@nl
type
label
Evaluation of various static i ...... al of an investigational drug.
@en
Evaluation of various static i ...... al of an investigational drug.
@nl
prefLabel
Evaluation of various static i ...... al of an investigational drug.
@en
Evaluation of various static i ...... al of an investigational drug.
@nl
P2093
P2860
P356
P1476
Evaluation of various static i ...... al of an investigational drug.
@en
P2093
A Fretland
D Plowchalk
E G Berglund
H J Einolf
I Ragueneau-Majlessi
J Y L Chien
P2860
P304
P356
10.1038/CLPT.2013.187
P407
P577
2013-09-18T00:00:00Z